Scientific Interest(s):
Dr. Steven Dubinett's research encompasses several areas of translational investigation in lung cancer. The primary focus of study assesses the impact of tumor cyclooxygenase 2 (COX-2) in lung cancer. He and his colleagues are investigating COX-2-dependent gene and protein expression and determining how these modify tumor invasion, angiogenesis, immunity and apoptosis in non-small cell lung cancer (NSCLC). Identification of COX-2 dependent gene regulation will allow the researchers to define new biomarkers in the COX-2 inhibitor-mediated antitumor response. Novel genes and pathways for future targeted therapies are also being identified and studied.
Selected Cancer-Related Publications:
Cui X, Zhang L, Luo J, Rajasekaran A, Hazra S, Cacalano N, Dubinett SM. Unphosphorylated STAT6 contributes to constitutive cyclooxygenase-2 expression in human non-small cell lung cancer. Oncogene. 2007; 26(29): 4253-60.
Hazra S, Batra RK, Tai HH, Sharma S, Cui X, Dubinett SM. Pioglitazone and rosiglitazone decrease prostaglandin E2 in non-small-cell lung cancer cells by up-regulating 15-hydroxyprostaglandin dehydrogenase. Mol Pharmacol. 2007; 71(6): 1715-20.
Lee JM, Mao JT, Krysan K, Dubinett SM. Significance of cyclooxygenase-2 in prognosis, targeted therapy and chemoprevention of NSCLC. Future Oncol. 2007; 3(2): 149-53.
Liu M, Yang SC, Sharma S, Luo J, Cui X, Peebles KA, Huang M, Sato M, Ramirez RD, Shay JW, Minna JD, Dubinett SM. EGFR Signaling is Required for TGF-{beta}1-mediated COX-2 Induction in Human Bronchial Epithelial Cells. Am J Respir Cell Mol Biol. 2007.
Lu QY, Jin YS, Zhang ZF, Le AD, Heber D, Li FP, Dubinett SM, Rao JY. Green tea induces annexin-I expression in human lung adenocarcinoma A549 cells: involvement of annexin-I in actin remodeling. Lab Invest. 2007; 87(5): 456-65.